Works by Verburgh, E.

Results: 10
    1

    Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa.

    Published in:
    SAMJ: South African Medical Journal, 2011, v. 101, n. 12, p. 900
    By:
    • Louw, V. J.;
    • Bassa, F.;
    • Chan, S. W.;
    • Dreosti, L.;
    • du Toit, M.;
    • Ferreira, M.;
    • Gartrell, K.;
    • Gunther, K.;
    • Jogessar, V.;
    • Littleton, N.;
    • Mahlangu, J.;
    • McDonald, A.;
    • Patel, M.;
    • Pool, R.;
    • Ruff, P.;
    • Schmidt, A.;
    • Sissolak, G.;
    • Swart, A.;
    • Verburgh, E.;
    • Webb, M. J.
    Publication type:
    Article
    2

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
    By:
    • McDonald, A.;
    • Verburgh, E.;
    • Gotti, M.;
    • Pinto, A.;
    • Zaucha, J.;
    • Ivanov, V.;
    • Melnichenko, V.;
    • Mocikova, H.;
    • Ozcan, M.;
    • Patti, C.;
    • Farias, J.;
    • Goncalves, I.;
    • Kuchkova, O.;
    • Mayer, J.;
    • Saydam, G.;
    • Tomassetti, S.;
    • Pathiraja, K.;
    • Ryland, K.;
    • Chakraborty, S.;
    • Jurczak, W.
    Publication type:
    Article
    3

    Progress in advanced cellular and gene therapies in South Africa and barriers to patient access: A National Consortium paper on behalf of the BloodSA Cell and Gene Therapy working party.

    Published in:
    SAMJ: South African Medical Journal, 2025, v. 115, n. 5, p. 21, doi. 10.7196/SAMJ.2025.v115i5.3070
    By:
    • Hendricks, C. L.;
    • Viljoen, I.;
    • Botes, M.;
    • Brittain, D.;
    • Mahlangu, J.;
    • Verburgh, E.;
    • Gerdener, T.;
    • Herd, C.;
    • Logan, M. G.;
    • Marais, A. L.;
    • Glatt, T. N.;
    • Cockeran, R.;
    • Poole, C.;
    • du Toit, J.;
    • Pepper, M. S.
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10